Risk of recurrence in chronic hepatitis B patients developing hepatocellular carcinoma with antiviral secondary prevention failure

BACKGROUND: Nucleos(t)ide analogues (NUCs) treatment can reduce the risk of hepatocellular carcinoma (HCC) development and recurrence in chronic hepatitis B (CHB) patients. However, the risk of recurrence in CHB patients who develop HCC despite NUC treatment remains unclear. METHODS: 167 consecutive...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, I-Cheng, Chau, Gar-Yang, Yeh, Yi-Chen, Chao, Yee, Huo, Teh-Ia, Su, Chien-Wei, Lin, Han-Chieh, Hou, Ming-Chih, Huang, Yi-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703552/
https://www.ncbi.nlm.nih.gov/pubmed/29176777
http://dx.doi.org/10.1371/journal.pone.0188552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5703552/
https://www.ncbi.nlm.nih.gov/pubmed/29176777
http://dx.doi.org/10.1371/journal.pone.0188552

Ejemplares similares